Columbus, OH, United States of America

Jennifer A Woyach

USPTO Granted Patents = 1 

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 2018

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Inventor Spotlight: Jennifer A. Woyach

Introduction

Jennifer A. Woyach, based in Columbus, OH, is a prominent inventor known for her contributions to the field of biochemistry and cancer treatment. She has made significant strides in understanding resistance mechanisms to targeted therapies, particularly in the context of BTK inhibitors, which are critical in treating various cancers.

Latest Patents

Woyach holds a patent for "Phospholipase C gamma 2 and resistance associated mutations." This patent describes a mutation that confers resistance to treatment with a BTK inhibitor. Specifically, it covers a modified PLCγ2 polypeptide that is altered at amino acid positions 742, 845, or 1140. This modified polypeptide exhibits decreased inhibition to covalent and/or irreversible BTK inhibitors. The patent also details diagnostic methods for detecting this modified polypeptide and the nucleic acid that encodes it, as well as the applications of these methods. Furthermore, it includes compositions, combinations, and kits that utilize the modified polypeptide, highlighting its potential as a screening agent for the identification and design of PLCγ2 inhibitors.

Career Highlights

Jennifer Woyach has made remarkable contributions to cancer research, particularly through her work at Pharmacyclics, Inc. Her focus on the molecular mechanisms underlying drug resistance in cancer therapies has positioned her as a leading expert in her field. Her innovative approaches towards developing diagnostic and therapeutic methods continue to impact treatment strategies for patients facing resistant cancers.

Collaborations

Throughout her career, Woyach has collaborated with fellow researchers and colleagues, notably John C. Byrd. Their partnership reflects a commitment to advancing the understanding of cancer biology and developing targeted therapies that improve patient outcomes. Collaborations like these are essential for fostering innovation and translating research findings into clinical applications.

Conclusion

Jennifer A. Woyach is a trailblazer in her field, with a noteworthy patent that addresses crucial issues in cancer treatment. Her work at Pharmacyclics, Inc., alongside esteemed colleagues, exemplifies the collaborative spirit of scientific research. As she continues to push the boundaries of what is possible in cancer therapy, her contributions will undoubtedly benefit countless patients and advance the field of medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…